Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.38 |
| ▸ | MTOR | P42345 | 6/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623943 | 1.00 | CDK6 (0.39) | CDK6HPGDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL20749376 | 0.89 | CDK6 (0.37) | CDK6HPGDPIK3CDPIK3CAPIK3CB | |
| Uplarafenib SCHEMBL14716189 | 0.84 | BRAF (0.51) | CDK6HPGDPIK3CDPIK3CAPIK3CB | |
| Uplarafenib SCHEMBL29623930 | 0.84 | BRAF (0.51) | CDK6HPGDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL14716175 | 0.83 | BRAF (0.33) | BRAFFGFR2NPC1 | |
| SCHEMBL29624095 | 0.82 | HPGD (0.42) | CDK6HPGDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL14716099 | 0.81 | BRAF (0.38) | HPGDBRAFNPC1 | |
| SCHEMBL14829458 | 0.81 | HPGD (0.46) | CDK6HPGDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL14716024 | 0.80 | BRAF (0.48) | CDK6HPGDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL14716305 | 0.80 | BRAF (0.46) | CDK6HPGDPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116880-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2024-04-11 | — | — | US | disclosed |
| CN-116887833-A | Certain chemical entities, compositions and methods | 润新生物公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2022119905-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2747767-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2747767-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10137125-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20160303118-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2016-10-20 | — | — | US | disclosed |
| US-9295671-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9295671-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9295671-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2747767-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013032951-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013032951-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116880-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, RB1 | CDK6 1103/4885HPGD 553/4885PIK3CD 953/4885 |
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | CDK6 38/4885HPGD 650/4885PIK3CD 319/4885 |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | PDXK, BRAF, CHEK1 | CDK6 38/4885HPGD 650/4885PIK3CD 319/4885 |
| US-20160303118-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | CDK6 38/4885HPGD 650/4885PIK3CD 319/4885 |
| US-10137125-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | PDXK, CHEK1, CHEK2 | CDK6 49/4885HPGD 558/4885PIK3CD 367/4885 |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | BRAF, PIK3CA, PLK1 | CDK6 110/4885HPGD 1616/4885PIK3CD 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.